Updates are available Correction dated 2019-05-08
Click to view Correction: https://doi.org/10.1038/s41581-019-0156-1
-
Authors
Phipps, Elizabeth A.
Thadhani, Ravi
Benzing, Thomas
Karumanchi, S. Ananth http://orcid.org/0000-0002-2281-6831
- License Information
-
More Information
Article History
First Online: 21 February 2019
Change Date: 8 May 2019
Change Type: Correction
Change Details: In the version of this article originally published online, the date when Francois Mauriceau published one of the earliest descriptions of pre-eclampsia was incorrectly stated to be 1637, which is actually his year of birth. The work was published in 1668. This error has been corrected in the PDF and HTML versions of the article.
Competing interests
: S.A.K. is co-inventor on multiple patents (US Patent and Trademark Office (USPTO) #7,740,849, #7,407,658, #7,335,362, #7,344,892 and #8969322B2) related to the use of angiogenic markers for the diagnosis, prediction and therapy of pre-eclampsia. R.T. is a co-inventor on a patent (USPTO #7,344,892) related to the use of angiogenic proteins for the prediction of pre-eclampsia. These patents are held at Harvard Hospitals (Beth Israel Deaconess Medical Center and Massachusetts General Hospital). S.A.K and R.T. have financial interests in Aggamin Therapeutics LLC and have previously served as consultants for Roche Diagnostics and ThermoFisher. S.A.K. has received a research grant from Siemens. R.T. and T.B. have received a research grant from Kaneka Pharmaceuticals. The other authors report no competing interests.
